YM, Oncoscience Finish Patient Enrollment in Nimotuzumab Trial

YM BioSciences announced that Oncoscience, its German partner for the development of nimotuzumab, a humanized EGFR-targeting monoclonal antibody, has recruited the final patient in its international Phase III trial that will combine the drug with radiation for the treatment of children and adolescents with diffuse intrinsic pontine glioma (DIPG), an inoperable form of brain cancer. 

According to YM, nimotuzumab has been designated an orphan drug by the EMEA.

The company added that the Phase III trial is being conducted in Germany. The primary endpoint of the trial is progression-free survival with overall survival as a secondary endpoint.